vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Cheer Holding, Inc. (CHR). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $71.0M, roughly 1.1× Cheer Holding, Inc.). Cheer Holding, Inc. runs the higher net margin — 10.9% vs -9.6%, a 20.5% gap on every dollar of revenue. On growth, Cheer Holding, Inc. posted the faster year-over-year revenue change (-0.1% vs -16.8%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

BIOX vs CHR — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.1× larger
BIOX
$77.6M
$71.0M
CHR
Growing faster (revenue YoY)
CHR
CHR
+16.7% gap
CHR
-0.1%
-16.8%
BIOX
Higher net margin
CHR
CHR
20.5% more per $
CHR
10.9%
-9.6%
BIOX

Income Statement — Q1 FY2026 vs Q2 FY2025

Metric
BIOX
BIOX
CHR
CHR
Revenue
$77.6M
$71.0M
Net Profit
$-7.4M
$7.8M
Gross Margin
46.8%
70.7%
Operating Margin
9.3%
11.7%
Net Margin
-9.6%
10.9%
Revenue YoY
-16.8%
-0.1%
Net Profit YoY
-20.2%
-37.5%
EPS (diluted)
$-0.12
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CHR
CHR
Q3 25
$77.6M
Q2 25
$71.0M
Q1 25
$60.6M
Q4 24
$98.8M
Q3 24
$93.3M
Q2 24
$71.1M
Q1 24
$84.0M
Q4 23
$140.2M
Net Profit
BIOX
BIOX
CHR
CHR
Q3 25
$-7.4M
Q2 25
$7.8M
Q1 25
$-1.6M
Q4 24
$605.2K
Q3 24
$-6.2M
Q2 24
$12.4M
Q1 24
$9.8M
Q4 23
$1.2M
Gross Margin
BIOX
BIOX
CHR
CHR
Q3 25
46.8%
Q2 25
70.7%
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
73.4%
Q1 24
50.8%
Q4 23
36.7%
Operating Margin
BIOX
BIOX
CHR
CHR
Q3 25
9.3%
Q2 25
11.7%
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q2 24
16.4%
Q1 24
15.7%
Q4 23
12.0%
Net Margin
BIOX
BIOX
CHR
CHR
Q3 25
-9.6%
Q2 25
10.9%
Q1 25
-2.6%
Q4 24
0.6%
Q3 24
-6.6%
Q2 24
17.5%
Q1 24
11.6%
Q4 23
0.9%
EPS (diluted)
BIOX
BIOX
CHR
CHR
Q3 25
$-0.12
Q2 25
$0.67
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.10
Q2 24
$1.23
Q1 24
$0.14
Q4 23
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CHR
CHR
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$322.1M
Total Assets
$734.9M
$362.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CHR
CHR
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
$186.1M
Q1 24
$16.4M
Q4 23
$24.4M
Stockholders' Equity
BIOX
BIOX
CHR
CHR
Q3 25
$288.3M
Q2 25
$322.1M
Q1 25
$345.0M
Q4 24
$346.3M
Q3 24
$346.0M
Q2 24
$286.1M
Q1 24
$348.5M
Q4 23
$335.3M
Total Assets
BIOX
BIOX
CHR
CHR
Q3 25
$734.9M
Q2 25
$362.7M
Q1 25
$798.2M
Q4 24
$835.2M
Q3 24
$827.3M
Q2 24
$333.2M
Q1 24
$836.1M
Q4 23
$819.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CHR
CHR
Operating Cash FlowLast quarter
$14.4M
$3.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CHR
CHR
Q3 25
$14.4M
Q2 25
$3.9M
Q1 25
$23.3M
Q4 24
$-5.4M
Q3 24
$5.2M
Q2 24
$-6.7M
Q1 24
$-17.4M
Q4 23
$21.1M
Cash Conversion
BIOX
BIOX
CHR
CHR
Q3 25
Q2 25
0.51×
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
-0.54×
Q1 24
-1.78×
Q4 23
17.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons